Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topsalysin - Sophiris Bio

Drug Profile

Topsalysin - Sophiris Bio

Alternative Names: PRX-302; PSA-PA 1; PSA-PAH 1

Latest Information Update: 04 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University; University of Victoria
  • Developer Sophiris Bio
  • Class Antineoplastics; Bacterial toxins; Pore forming cytotoxic proteins; Urologics
  • Mechanism of Action Apoptosis stimulants; Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Benign prostatic hyperplasia
  • Phase II Prostate cancer

Most Recent Events

  • 20 Jun 2019 Sophiris Bio receives positive feedback from EMA regarding planned phase III localised Prostate cancer clinical trial design
  • 25 Apr 2019 Sophiris Bio has patent protection for topsalysin in worldwide
  • 13 Mar 2019 Sophiris Bio completes phase IIb trial for Prostate cancer in USA and United Kingdom (Intraprostatic) (NCT03081481)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top